Tellgen Corporation

Equities

300642

CNE100002P42

Medical Equipment, Supplies & Distribution

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
14.39 ^CNY	+0.21%		+11.03%	-18.47%

Apr. 22	Tellgen Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 01	Tranche Update on Tellgen Corporation's Equity Buyback Plan announced on February 6, 2024.	CI

Tellgen Corporation Approves Cash Dividend for 2022, Payable on 23 May 2023

May 15, 2023 at 03:33 pm EDT

Tellgen Corporation at the Annual General Meeting held on 12 May 2023, approved cash dividend (tax included) of CNY 2.00000000 per 10 shares for 2022. Record date is 22 May 2023; Ex-date is 23 May 2023; Payment date is 23 May 2023.

Latest news about Tellgen Corporation

Tellgen Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 22	CI
Tranche Update on Tellgen Corporation's Equity Buyback Plan announced on February 6, 2024.	Apr. 01	CI
Tellgen Corporation announces an Equity Buyback for CNY 50 million worth of its shares.	Feb. 06	CI
Tellgen Corporation authorizes a Buyback Plan.	Feb. 05	CI
Tellgen Corporation Announces Board Appointments	Dec. 26	CI
Tellgen Corporation Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-24	CI
Tellgen Corporation, Shanghai Tellgen Diagnostic Technology Co., Ltd., Shanghai Maishi Jingwu Enterprise Management Partnership Enterprise (Limited Partnership), Yao Beier, Niu Zhengxiang and Zhan Hong agreed to acquire additional 5.71% stake in Shanghai Maishi Biotechnology Co., Ltd. from Wu Liang for CNY 1.4 million.	23-09-27	CI
Tellgen Corporation Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-18	CI
Tellgen Corporation Approves Cash Dividend for 2022, Payable on 23 May 2023	23-05-15	CI
Tellgen Corporation Proposes Final Cash Dividend for 2022	23-04-24	CI
Tellgen Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-21	CI
Tellgen Corporation Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-28	CI
Tranche Update on Tellgen Corporation's Equity Buyback Plan announced on October 27, 2021.	22-10-26	CI
Tellgen Corporation's Equity Buyback announced on October 27, 2021, has expired with 1,062,840 shares, representing 0.65% for CNY 25.43 million.	22-10-24	CI
Tranche Update on Tellgen Corporation's Equity Buyback Plan announced on October 27, 2021.	22-10-10	CI
Tellgen Corporation Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-19	CI
Tranche Update on Tellgen Corporation's Equity Buyback Plan announced on October 27, 2021.	22-07-03	CI
Tellgen Corporation Announces Final Distribution on A Shares for the Year 2021, Payable on 24 May 2022	22-05-17	CI
Tellgen Corporation Approves Cash Dividend for the Year 2021	22-05-16	CI
Tellgen Corporation Announces Profit Distribution Proposal for 2021	22-04-25	CI
Tellgen Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-22	CI
Tellgen Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-22	CI
Tranche Update on Tellgen Corporation's Equity Buyback Plan announced on October 27, 2021.	22-04-01	CI
Tranche Update on Tellgen Corporation's Equity Buyback Plan announced on October 27, 2021.	22-01-04	CI
Tellgen Corporation announces an Equity Buyback for CNY 50 million worth of its shares.	21-10-26	CI

Chart Tellgen Corporation

Duration

Period

More charts

Company Profile

Tellgen Corp is a company engaged in research, development, production and sales of in vitro diagnostic reagents and instruments. The Company's products are comprised of immunodiagnostic products, molecular diagnostic products and biochemical diagnostic products, including tumor marker detection products, human papillomavirus (HPV) nucleic acid testing products, autoimmune disease detection products and lung cancer methylation mutation detection products.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-14 - Annual General Meeting

More about the company

	1st Jan change	Capi.
TELLGEN CORPORATION	-18.47%	324M
BIOMÉRIEUX	-0.60%	12.63B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-9.59%	7.67B
DIASORIN S.P.A.	+1.82%	5.42B
AUTOBIO DIAGNOSTICS CO., LTD.	+0.02%	4.57B
LANTHEUS HOLDINGS, INC.	+7.32%	4.56B
10X GENOMICS, INC.	-47.68%	3.51B
ANDON HEALTH CO., LTD.	+6.42%	2.59B
VITROLIFE AB	-14.59%	2.05B
MYRIAD GENETICS, INC.	+2.25%	1.77B

Diagnostic & Testing Substances